Update
$Syndax Pharmaceuticals(SNDX.US$ Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment
MT Newswires· 1 min ago
Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer.
The company said the filing was assigned a prescription drug user fee act target action date of Sept. 26.
MT Newswires· 1 min ago
Syndax Pharmaceuticals (SNDX) said late Tuesday the US Food and Drug Administration has granted priority review for the company's new drug application for revumenib to treat relapsed or refractory acute leukemia, a type of cancer.
The company said the filing was assigned a prescription drug user fee act target action date of Sept. 26.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
